| __timestamp | Sarepta Therapeutics, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 94231000 | 293000 |
| Thursday, January 1, 2015 | 146394000 | 1002000 |
| Friday, January 1, 2016 | 188272000 | 888000 |
| Sunday, January 1, 2017 | 166707000 | 19623000 |
| Monday, January 1, 2018 | 401843000 | 30421000 |
| Tuesday, January 1, 2019 | 560909000 | 34794000 |
| Wednesday, January 1, 2020 | 722343000 | 28304000 |
| Friday, January 1, 2021 | 771182000 | 56886000 |
| Saturday, January 1, 2022 | 877090000 | 100894000 |
| Sunday, January 1, 2023 | 877387000 | 159765000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Sarepta Therapeutics, Inc. has consistently outpaced Viridian Therapeutics, Inc. in R&D investments. From 2014 to 2023, Sarepta's R&D budget surged by over 830%, peaking at nearly $880 million in 2023. This robust growth underscores Sarepta's commitment to advancing its therapeutic pipeline.
In contrast, Viridian Therapeutics, Inc. has shown a more modest increase, with R&D expenses growing from a mere $293,000 in 2014 to approximately $160 million in 2023. This represents a remarkable 54,000% increase, highlighting Viridian's strategic shift towards innovation. The data reveals a compelling narrative of two companies navigating the biotech sector with distinct strategies, reflecting broader industry trends towards increased R&D spending.
Eli Lilly and Company vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending
AbbVie Inc. vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending
Novartis AG vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc.
BeiGene, Ltd. vs Sarepta Therapeutics, Inc.: Strategic Focus on R&D Spending
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.
Bio-Techne Corporation or Viridian Therapeutics, Inc.: Who Invests More in Innovation?
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and MannKind Corporation
Research and Development: Comparing Key Metrics for Corcept Therapeutics Incorporated and Viridian Therapeutics, Inc.
Comparing Innovation Spending: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.